Regeneron Stock Surges 8.38% in Three Days, Trading Volume Hits $6.16 Billion Ranking 156th

On June 10, 2025, Regeneron Pharmaceuticals Inc. (REGN) saw a 1.15% increase in its stock price, marking the third consecutive day of gains with a total increase of 8.38% over the past three days. The company's trading volume reached $6.16 billion, placing it at the 156th position in the day's trading activity.

Regeneron's Libtayo immunotherapy has shown remarkable results in a phase 3 trial, significantly reducing the risk of cancer recurrence or death by 68% for patients with high-risk cutaneous squamous cell carcinoma. This breakthrough positions Regeneron at the forefront of cancer treatment innovation, potentially driving stock valuations upwards and attracting investor interest.

Analysts are optimistic about Regeneron's potential in the COPD treatment market with its drug Itepekimab, particularly for former smokers. Despite some risks associated with phase 3 results, RBC Capital Markets sees significant potential in this area, which could further boost the company's stock performance.

Interim results from a Phase 2 obesity study indicate that Regeneron's semaglutide-trevogrumab combination is effective in aiding fat loss while preserving lean mass. This development expands Regeneron's footprint in the obesity treatment segment, although investor sentiments remain tied to ongoing trial results.

Regeneron's strategic partnership with Hansoh Pharmaceutical Group for the development of obesity and diabetes therapies marks a significant expansion in their portfolio. This collaboration is expected to enhance Regeneron's relevance in metabolic treatments and fuel investor enthusiasm.

Both Bernstein and DBS Bank have adjusted their price targets for Regeneron, with Bernstein setting it at $750 and DBS Bank increasing theirs to $760. These revisions reflect analyst confidence and favorable market perceptions towards Regeneron, aligning with the company's strategic breakthroughs and financial health.